Literature DB >> 9513724

Role of epidermal growth factor receptor family members in growth and differentiation of breast carcinoma.

B D Cohen1, C B Siegall, S Bacus, L Foy, J M Green, I Hellström, K E Hellström, H P Fell.   

Abstract

Members of the epidermal growth factor (EGF) family of tyrosine kinase receptors are involved in the regulation of cell growth and differentiation, and are found to be expressed in many types of cancers. Activation of these receptors can be elicited by multiple ligands, resulting in the formation of a spectrum of heterodimer complexes and a number of biological outcomes. A clear demonstration of biological activation by a single complex has been difficult to address because of the endogenous expression of HERs (human EGF-like receptors) in many cell lines. We have generated a collection of cell lines expressing all HERs alone or in all pairwise combinations in a clone of NIH 3T3 cells (3T3-7d) devoid of detectable EGF receptor family members. Transformation, as measured by growth in soft agar, only occurred in cells expressing two different HER family members. Transformation with activated Neu and the rate of in vivo tumour formation were also correlated with the expression of multiple HERs in the same cell. To further our understanding of the role of heterodimer signalling, we demonstrated that, within a breast carcinoma cell line, activation of HER-3 results in cellular differentiation, prolonged activation of extracellular-signal-related kinase 1 (ERK1) activity and an increase in p21CIP1/WAF1 nuclear staining. In contrast, activation of HER-4 is mitogenic, induces transient activation of ERK1 activity and decreases the nuclear staining of p21CIP1/WAF1. These differences in biochemical and biological responses are correlated with the contrasting abilities of HER-3 and HER-4 to be down-regulated from the cell surface. The cell-surface localization of HER-3 does not change in response to ligand, whereas activation of HER-4 results in a loss of cell-surface staining followed by accumulation into a perinuclear compartment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9513724

Source DB:  PubMed          Journal:  Biochem Soc Symp        ISSN: 0067-8694


  6 in total

1.  The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism.

Authors:  Jason D Prescott; Karen S N Koto; Meenakshi Singh; Arthur Gutierrez-Hartmann
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

2.  Prognostic significance of serum ERBB3 and ERBB4 mRNA in lung adenocarcinoma patients.

Authors:  Mirza Masroor; Jamsheed Javid; Rashid Mir; Prasant Y; Imtiyaz A; Mariyam Z; Anant Mohan; P C Ray; Alpana Saxena
Journal:  Tumour Biol       Date:  2015-08-09

3.  The polymorphism of EGFR 142285G > A exerts no risk effect on breast cancer.

Authors:  Qingcun Zheng; Ruiying Chen; Liqin Luan; Junrui Li; Suling Gao
Journal:  Tumour Biol       Date:  2013-10-28

4.  In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies.

Authors:  Yoshinori Koyama; Tristan Barrett; Yukihiro Hama; Gregory Ravizzini; Peter L Choyke; Hisataka Kobayashi
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

5.  Multicolor in vivo targeted imaging to guide real-time surgery of HER2-positive micrometastases in a two-tumor coincident model of ovarian cancer.

Authors:  Michelle Longmire; Nobuyuki Kosaka; Mikako Ogawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancer Sci       Date:  2009-03-16       Impact factor: 6.716

6.  TGF-β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways.

Authors:  Yuanyuan Zhao; Jing Ma; Yanling Fan; Zhiyong Wang; Ran Tian; Wei Ji; Fei Zhang; Ruifang Niu
Journal:  Mol Oncol       Date:  2018-01-24       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.